EVERARDO MEJIA: Open Payments
NPI 1144491259 · EL MONTE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,244 in 99 payments from 14 companies in 2025. Trend: 2023 $2,559 · 2024 $3,339 · 2025 $2,244
Food & beverage: $2,244
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 25 | $659 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $471 |
| ABBVIE INC. | 11 | $254 |
| E.R. Squibb & Sons, L.L.C. | 9 | $215 |
| Neurocrine BioSciences, Inc. | 6 | $190 |
| Teva Pharmaceuticals USA, Inc. | 8 | $151 |
| Otsuka America Pharmaceutical, Inc. | 5 | $116 |
| Novo Nordisk Inc | 2 | $43 |
| Lilly USA, LLC | 2 | $39 |
| Axsome Therapeutics, Inc. | 1 | $28 |
Products named: FANAPT, CAPLYTA, VRAYLAR, COBENFY, INGREZZA, REXULTI, UZEDY, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
